heat biologics is a clinical-stage company focused on developing its proprietary impact™ (immune pan-antigen cytotoxic therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers. heat's impact therapy is a first-in-class, fully human immunotherapy that functions as both an immune stimulator and an antigen-delivery system. impact effectively transforms living allogeneic cells into "osmotic pumps" that continuously secrete cancerous antigens to robustly stimulate the immune system against the targeted cancer. impact therapy is applicable to a wide range of cancers. heat is currently conducting two phase 2 clinical trials with its hs-110 to treat non-small cell lung cancer (nsclc) and its hs-410 to treat bladder cancer.
Company profile
Ticker
SCPX
Exchange
Website
CEO
Jeffrey Wolf
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
HEAT BIOLOGICS, INC., NightHawk Biosciences, Inc.
SEC CIK
Corporate docs
Subsidiaries
Heat Biologics I, Inc • Heat Biologics III, Inc. • Heat Biologics IV, Inc. • Heat Biologics GmbH • Heat Biologics Australia Pty LTD • Zolovax, Inc. • Scorpius Biomanufacturing, Inc. • 1Formerly Heat Biologics II, Inc. ...
IRS number
262844103
SCPX stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
26 Aug 24
10-Q
2024 Q2
Quarterly report
19 Aug 24
8-K
Scorpius Holdings, Inc. Announces Pricing of Public Offering
19 Aug 24
424B4
Prospectus supplement with pricing info
16 Aug 24
NT 10-Q
Notice of late quarterly filing
15 Aug 24
8-K
Scorpius Holdings, Inc. Provides Update on Its Previously Announced Public Offering
9 Aug 24
EFFECT
Notice of effectiveness
7 Aug 24
FWP
Free writing prospectus
6 Aug 24
8-K
Results of Operations and Financial Condition
31 Jul 24
S-1/A
IPO registration (amended)
31 Jul 24
Latest ownership filings
SC 13G
3i, LP
26 Sep 24
SC 13G
Jaigobind Ramnarain Joseph
6 Sep 24
SC 13D/A
Wolf Jeffrey Alan
21 May 24
4
Jeffrey Alan Wolf
17 May 24
SC 13D/A
Wolf Jeffrey Alan
14 May 24
SC 13D/A
Wolf Jeffrey Alan
12 Dec 23
SC 13D/A
Wolf Jeffrey Alan
21 Aug 23
SC 13D/A
Wolf Jeffrey Alan
30 Dec 22
4
Jeffrey Alan Wolf
9 Dec 22
4
Edward B Smith III
9 Dec 22
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.47 mm | 1.47 mm | 1.47 mm | 1.47 mm | 1.47 mm | 1.47 mm |
Cash burn (monthly) | 27.58 k | 363.71 k | 3.09 mm | 2.69 mm | 2.18 mm | 1.73 mm |
Cash used (since last report) | 80.00 k | 1.06 mm | 8.98 mm | 7.81 mm | 6.32 mm | 5.02 mm |
Cash remaining | 1.39 mm | 417.03 k | -7.50 mm | -6.34 mm | -4.85 mm | -3.54 mm |
Runway (months of cash) | 50.5 | 1.1 | -2.4 | -2.4 | -2.2 | -2.0 |
Institutional ownership, Q2 2024
52.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 1 |
Closed positions | 11 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 11.13 mm |
Total shares | 1.63 mm |
Total puts | 0.00 |
Total calls | 700.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 1.62 mm | $11.13 mm |
Wolf Jeffrey Alan | 11.03 k | $1.00 k |
Simplex Trading | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 May 24 | Wolf Jeffrey Alan | Common Stock | Grant | Acquire A | No | No | 0 | 2,500,000 | 0.00 | 3,572,789 |
16 May 24 | Wolf Jeffrey Alan | Warrant Common Stock | Grant | Acquire A | No | No | 0.12 | 2,500,000 | 300.00 k | 2,500,000 |
News
Scorpius Holdings CEO Jeff Wolf Provides Corporate Update
26 Aug 24
Scorpius Holdings Q2 EPS $(26.98), Sales $759.94K Up From $657.78K YoY
20 Aug 24
Scorpius Holdings Announces New Pricing of $12.5M Underwritten Public Offering of 12.5M Shares of Common Stock or Pre-Funded Warrants
16 Aug 24
Nasdaq Jumps 250 Points; Disney Earnings Beat Estimates
7 Aug 24
Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
7 Aug 24
Press releases
Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA
9 Sep 24
Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024
20 Aug 24
Scorpius Holdings, Inc. Announces Closing of Public Offering
19 Aug 24
Scorpius Holdings, Inc. Announces Pricing of Public Offering
16 Aug 24
Scorpius Holdings, Inc. Provides Update on its Previously Announced Public Offering
9 Aug 24